Details of the Drug-Related molecule(s) Interaction Atlas

General Information of DTT (ID: TTCJG29)

• DTT Name: Serine/threonine-protein kinase mTOR (mTOR) DTT Info
• Gene Name: MTOR

Molecule-Related Drug & Molecule List

6 Approved Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Everolimus	DM8X2EH	Advanced cancer	2A00-2F9Z	Approved	[1]
Novolimus	DM6ZPLQ	Artery stenosis	BD52	Approved	[2]
PF-04449913	DMSB068	Chronic myelomonocytic leukaemia	2A40	Approved	[3]
Sirolimus	DMGW1ID	Advanced cancer	2A00-2F9Z	Approved	[4]
Temsirolimus	DMS104F	Renal cell carcinoma	2C90	Approved	[5]
Zotarolimus	DMRMCXW	Solid tumour/cancer	2A00-2F9Z	Approved	[6]

26 Clinical Trial Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Ridaforolimus	DMLHEU7	Sarcoma	2A60-2C35	Phase 3	[7]
ABI-009	DMQ6KZM	Malignant perivascular epithelioid cell tumour	2B5Y	Phase 2	[8]
AZD2014	DMOEARH	Solid tumour/cancer	2A00-2F9Z	Phase 2	[9]
BEZ235	DMKBRDL	Solid tumour/cancer	2A00-2F9Z	Phase 2	[10]
GDC-0980/RG7422	DMF3MV1	Non-hodgkin lymphoma	2B33.5	Phase 2	[2]
INK128	DMGO7QT	Breast cancer	2C60-2C65	Phase 2	[11]
LY3023414	DMD9KYF	Prostate cancer	2C82.0	Phase 2	[12]
MM-141	DM2RJ4D	Pancreatic cancer	2C10	Phase 2	[8]
OSI-027	DMJX3O8	Renal cell carcinoma	2C90	Phase 2	[13]
PF-04691502	DMS610L	Endometrial cancer	2C76	Phase 2	[14]
PF-05212384	DMBL3VD	Solid tumour/cancer	2A00-2F9Z	Phase 2	[15]
PQR309	DMMCYZ8	Squamous head and neck cell carcinom	2D60.0	Phase 2	[2]
Salirasib	DMRSU4X	Lung cancer	2C25.0	Phase 2	[2]
SAR245409	DMQM7IL	Solid tumour/cancer	2A00-2F9Z	Phase 2	[2]
SF1126	DML10K3	Head and neck cancer	2D42	Phase 2	[8]
BGT226	DMXKDUL	Solid tumour/cancer	2A00-2F9Z	Phase 1/2	[16]
CC-223	DMMQYL9	Solid tumour/cancer	2A00-2F9Z	Phase 1/2	[17]
ME-344	DM6JN19	Breast cancer	2C60-2C65	Phase 1/2	[18]
BI 860585	DMMQ12N	Solid tumour/cancer	2A00-2F9Z	Phase 1	[19]
CERC 006	DMM1NGC	Lymphatic malformation	LA90.1	Phase 1	[20]
DS-3078	DMG7I5J	Lymphoma	2A80-2A86	Phase 1	[21]
DS-7423	DMCFJM3	Solid tumour/cancer	2A00-2F9Z	Phase 1	[22]
GDC-0349	DM3Z2JB	Non-hodgkin lymphoma	2B33.5	Phase 1	[23]
LAM-001	DM7JNHU	Lymphangioleiomyomatosis	CB07	Phase 1	[24]
PWT-33597	DMJY15D	Solid tumour/cancer	2A00-2F9Z	Phase 1	[25]
VS-5584	DMMO3G5	Malignant mesothelioma	2C26.0	Phase 1	[2]

5 Patented Agent(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
PMID25726713-Compound-47	DMXE5KM	N. A.	N. A.	Patented	[26]
PMID25726713-Compound-48	DMSIOUA	N. A.	N. A.	Patented	[26]
PMID25726713-Compound-49	DM2CT4G	N. A.	N. A.	Patented	[26]
PMID25726713-Compound-50	DM3BDFV	N. A.	N. A.	Patented	[26]
PMID25726713-Compound-51	DMF0OW4	N. A.	N. A.	Patented	[26]

3 Discontinued Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
AZD8055	DM7L8SG	Solid tumour/cancer	2A00-2F9Z	Discontinued in Phase 1/2	[27]
TAFA-93	DMI52NT	Transplant rejection	NE84	Discontinued in Phase 1	[28]
SCR-44001	DMFZNUA	Solid tumour/cancer	2A00-2F9Z	Terminated	[29]

32 Investigative Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
(4-(6-morpholino-9H-purin-2-yl)phenyl)methanol	DMUOFW8	Discovery agent	N.A.	Investigative	[30]
2-(2-Methyl-morpholin-4-yl)-benzo[h]chromen-4-one	DMAHZR9	Discovery agent	N.A.	Investigative	[31]
2-(6-morpholino-9H-purin-2-yl)phenol	DMZDNHQ	Discovery agent	N.A.	Investigative	[30]
2-chloro-N-(6-cyanopyridin-3-yl)propanamide	DMBKVM4	Discovery agent	N.A.	Investigative	[32]
2-Morpholin-4-yl-pyrimido[2,1-a]isoquinolin-4-one	DM79ZOV	Discovery agent	N.A.	Investigative	[31]
3-(6-morpholino-9H-purin-2-yl)phenol	DMS2OY9	Discovery agent	N.A.	Investigative	[30]
4-(2-(1H-indol-6-yl)-9H-purin-6-yl)morpholine	DMTJGBL	Discovery agent	N.A.	Investigative	[30]
4-(2-(thiophen-2-yl)-9H-purin-6-yl)morpholine	DMWN1CM	Discovery agent	N.A.	Investigative	[30]
4-(2-(thiophen-3-yl)-9H-purin-6-yl)morpholine	DMAO6X9	Discovery agent	N.A.	Investigative	[30]
4-(6-morpholino-9H-purin-2-yl)phenol	DM1Z3N6	Discovery agent	N.A.	Investigative	[30]
AP-21967	DMCNG74	Discovery agent	N.A.	Investigative	[33]
AR-mTOR-26	DM24MKI	Solid tumour/cancer	2A00-2F9Z	Investigative	[2]
C-16-(S)-3-methylindolerapamycin	DMZXE6O	Discovery agent	N.A.	Investigative	[33]
CU-906	DMY1WEM	Solid tumour/cancer	2A00-2F9Z	Investigative	[2]
EC-0565	DMIC372	Solid tumour/cancer	2A00-2F9Z	Investigative	[2]
EC-0845	DMK6E10	Inflammation	1A00-CA43.1	Investigative	[2]
EM-101	DMQ63J2	Solid tumour/cancer	2A00-2F9Z	Investigative	[2]
Ethyl 1-[(1H-benzimidazol-2(3H)one-5-yl)sulfonyl]-1H-pyrrole-2-carboxylate	DM3FH02	Discovery agent	N.A.	Investigative	[31]
HM-5016699	DMKHVUE	Solid tumour/cancer	2A00-2F9Z	Investigative	[2]
OXA-01	DMCFM2E	Solid tumour/cancer	2A00-2F9Z	Investigative	[2]
P-2281	DMZI8QW	Ulcerative colitis	DD71	Investigative	[2]
P-6915	DMJDI7O	Solid tumour/cancer	2A00-2F9Z	Investigative	[2]
PF-03772304	DMJ0936	Solid tumour/cancer	2A00-2F9Z	Investigative	[34]
PF-05094037	DMZAE97	Solid tumour/cancer	2A00-2F9Z	Investigative	[2]
PP-242	DM2348V	Discovery agent	N.A.	Investigative	[35]
PP121	DMU8KTO	Discovery agent	N.A.	Investigative	[35]
Rapamycin complexed with immunophilin FKBP12	DMLBP3F	Discovery agent	N.A.	Investigative	[36]
SB-2280	DMIBS95	Solid tumour/cancer	2A00-2F9Z	Investigative	[2]
SX-MTR1	DMJGZ79	Bladder cancer	2C94	Investigative	[2]
torin 1	DMZD0NA	Discovery agent	N.A.	Investigative	[37]
Torin2	DMC6U93	T-cell leukaemia	2A90	Investigative	[38]
X-387	DMZ0TDL	Solid tumour/cancer	2A00-2F9Z	Investigative	[2]

References

• [1] Mammalian target of rapamycin, its mode of action and clinical response in metastatic clear cell carcinoma. Gan To Kagaku Ryoho. 2009 Jul;36(7):1076-9.
• [2] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2109).
• [3] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [4] Knockouts model the 100 best-selling drugs--will they model the next 100 Nat Rev Drug Discov. 2003 Jan;2(1):38-51.
• [5] Advances in kinase targeting: current clinical use and clinical trials. Trends Pharmacol Sci. 2014 Nov;35(11):604-20.
• [6] Natural products to drugs: natural product-derived compounds in clinical trials. Nat Prod Rep. 2008 Jun;25(3):475-516.
• [7] A novel c-Met inhibitor, MK8033, synergizes with carboplatin plus paclitaxel to inhibit ovarian cancer cell growth. Oncol Rep. 2013 May;29(5):2011-8.
• [8] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [9] Dramatic suppression of colorectal cancer cell growth by the dual mTORC1 and mTORC2 inhibitor AZD-2014. Biochem Biophys Res Commun. 2014 Jan 10;443(2):406-12.
• [10] The dual PI3K/mTOR inhibitor NVP-BEZ235 is a potent inhibitor of ATM- and DNA-PKCs-mediated DNA damage responses. Neoplasia. 2012 Jan;14(1):34-43.
• [11] 2011 Pipeline of Intellikine.
• [12] Company report (Lilly)
• [13] Targeting the phosphoinositide 3-kinase pathway in cancer. Nat Rev Drug Discov. 2009 Aug;8(8):627-44.
• [14] PF-04691502, a potent and selective oral inhibitor of PI3K and mTOR kinases with antitumor activity.Mol Cancer Ther.2011 Nov;10(11):2189-99.
• [15] First-in-Human Study of PF-05212384 (PKI-587), a Small-Molecule, Intravenous, Dual Inhibitor of PI3K and mTOR in Patients with Advanced Cancer. Clin Cancer Res. 2015 Apr 15;21(8):1888-95.
• [16] Simultaneous targeting of PI3K and mTOR with NVP-BGT226 is highly effective in multiple myeloma. Anticancer Drugs. 2012 Jan;23(1):131-8.
• [17] CC-223, a Potent and Selective Inhibitor of mTOR Kinase: In Vitro and In Vivo Characterization. Mol Cancer Ther. 2015 Jun;14(6):1295-305.
• [18] National Cancer Institute Drug Dictionary (drug id 728650).
• [19] Clinical pipeline report, company report or official report of tatcongress.
• [20] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2023. Adis Insight
• [21] A first-in-human Phase I study of DS-3078a, an oral TORC1/2 inhibitor, in patients with advanced solid tumors: Preliminary results, Mol Cancer Ther November,2013, 12, C173.
• [22] Antitumor activity and induction of TP53-dependent apoptosis toward ovarian clear cell adenocarcinoma by the dual PI3K/mTOR inhibitor DS-7423. PLoS One. 2014 Feb 4;9(2):e87220.
• [23] Discovery and Biological Profiling of Potent and Selective mTOR Inhibitor GDC-0349. ACS Med Chem Lett. 2012 Nov 29;4(1):103-7.
• [24] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [25] PIK3CA mutation H1047R is associated with response to PI3K/AKT/mTOR signaling pathway inhibitors in early phase clinical trials
• [26] Hedgehog inhibitors: a patent review (2013 - present).Expert Opin Ther Pat. 2015 May;25(5):549-65.
• [27] Clinical pipeline report, company report or official report of AstraZeneca (2009).
• [28] EP patent application no. 2275103, Mtor inhibitors in the treatment of endocrine tumors.
• [29] Early detection of response to experimental chemotherapeutic Top216 with [18F]FLT and [18F]FDG PET in human ovary cancer xenografts in mice. PLoS One. 2010 Sep 24;5(9):e12965.
• [30] Novel purine and pyrazolo[3,4-d]pyrimidine inhibitors of PI3 kinase-alpha: Hit to lead studies. Bioorg Med Chem Lett. 2010 Jan 15;20(2):636-9.
• [31] Selective benzopyranone and pyrimido[2,1-a]isoquinolin-4-one inhibitors of DNA-dependent protein kinase: synthesis, structure-activity studies, and... J Med Chem. 2005 Jan 27;48(2):569-85.
• [32] Synthesis and therapeutic evaluation of pyridyl based novel mTOR inhibitors. Bioorg Med Chem Lett. 2009 Jun 1;19(11):2949-52.
• [33] The rapamycin-binding domain of the protein kinase mammalian target of rapamycin is a destabilizing domain. J Biol Chem. 2007 May 4;282(18):13395-401.
• [34] Discovery of the Highly Potent PI3K/mTOR Dual Inhibitor PF-04979064 through Structure-Based Drug Design. ACS Med Chem Lett. 2012 Nov 7;4(1):91-7.
• [35] Targeted polypharmacology: discovery of dual inhibitors of tyrosine and phosphoinositide kinases. Nat Chem Biol. 2008 Nov;4(11):691-9.
• [36] Selected novel anticancer treatments targeting cell signaling proteins. Oncologist. 2001;6(6):517-37.
• [37] Discovery of 1-(4-(4-propionylpiperazin-1-yl)-3-(trifluoromethyl)phenyl)-9-(quinolin-3-yl)benzo[h][1,6]naphthyridin-2(1H)-one as a highly potent, selective mammalian target of rapamycin (mTOR) inhibitor for the treatment of cancer. J Med Chem. 2010 Oct 14;53(19):7146-55.
• [38] Torin2 Potentiates Anticancer Effects on Adult T-Cell Leukemia/Lymphoma by Inhibiting Mammalian Target of Rapamycin. Anticancer Res. 2016 Jan;36(1):95-102.